About Alvogen
Alvogen is a company based in Montville (United States) founded in 2009 was acquired by Lotus in September 2025. Alvogen has raised $155.92 million across 2 funding rounds from investors including Morgan Stanley, Lotus and IMM Investment. Alvogen has completed 7 acquisitions, including County Line Pharma, County Line Pharmaceuticals and Dolphin. Alvogen offers products and services including Generic Drugs and Injectables.
- Headquarter Montville, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Alvogen, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$155.92 M (USD)
in 2 rounds
-
Latest Funding Round
$100 M (USD), Series D
Jun 30, 2021
-
Investors
Morgan Stanley
& 4 more
-
Employee Count
Not available
-
Investments & Acquisitions
County Line Pharma
& 6 more
- Acquired by
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Alvogen
Alvogen offers a comprehensive portfolio of products and services, including Generic Drugs and Injectables.
Generic drugs are developed and marketed by Alvogen as part of its core portfolio to provide accessible alternatives to branded medications
Injectables are manufactured and distributed by Alvogen, focusing on complex, high-value products that support various medical treatments
People of Alvogen
Unlock access to complete
Funding Insights of Alvogen
Alvogen has successfully raised a total of $155.92M across 2 strategic funding rounds. The most recent funding activity was a Series D round of $100 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Alvogen
Alvogen has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Morgan Stanley, Lotus and IMM Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
IMM Investment is recognized as a leading multi-asset alternative investment firm in Asia.
|
Locked | Locked | Locked | |
|
Private equity investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Wealth management, investment advisory, and financial services are provided.
|
Locked | Locked | Locked |
Investor details for Alvogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Alvogen
Alvogen has strategically engaged in corporate development activities, having acquired 7 companies. Notable acquisitions include County Line Pharma, County Line Pharmaceuticals and Dolphin.
Investment portfolio details for Alvogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Online drug information is provided via GRALISE's digital platform.
|
Locked | Locked | 2010 | Locked | |
|
Generic solid and liquid dosage forms are manufactured and marketed.
|
Locked | Locked | 2007 | Locked | |
|
Generic pharmaceutical products are manufactured across therapeutic categories.
|
Locked | Locked | 2007 | Locked |
Complete acquisition details for Alvogen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Alvogen
Detailed financials for Alvogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Alvogen Comparisons
Peer comparison for Alvogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Alvogen
Detailed competitors of Alvogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Alvogen
Complete news archive for Alvogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alvogen
Alvogen was founded in 2009 and raised its 1st funding round 3 years after it was founded.
Alvogen is headquartered in Montville, United States. It is registered at Montville, New Jersey, United States.
Lisa Graver is the current CEO of Alvogen.
Alvogen is a funded company, having raised a total of $155.92M across 2 funding rounds to date.
Alvogen was founded in 2009 and is headquartered in Montville, United States. Operations in the pharmaceutical sector involve developing, in-licensing, manufacturing, and marketing a range of products, including generic drugs, branded items, injectables, and complex medications such as inhalation therapies and 505(b)(2) formulations. A research and development program supports the pipeline, while ethical practices and transparency guide interactions with healthcare providers.
Alvogen offers Generic Drugs and Injectables.
Alvogen has made 7 acquisitions, including County Line Pharma, County Line Pharmaceuticals, and Dolphin.
Alvogen has 5 investors. Key investors include Morgan Stanley, Lotus, IMM Investment, Aztiq, and Pamplona Capital Management.